iBio, Inc. (IBIO) stock
IBIONasdaqPharmaceutical PreparationsFiscal year ends June 30
$0.75+0.04 (+5.86%)
Close on Nov 17, 2026Market cap $48.11MP/E –Yield –
Earnings
iBio's quarterly results as reported in its earnings releases, with the company's own outlook. Hover a number to see the sentence it came from.
Next report
Feb 9, 2027
Q2 FY2027 · estimated, after the close
Revenue, Q1 FY2027
$1.10M
+1000.0% on a year earlier
EPS, Q1 FY2027
–
Latest guidance
None
No outlook given in releases
Quarterly results
Revenue and earnings per share from each of iBio's earnings releases, newest first
| Quarter | Reported | Revenue | YoY | EPS | Source |
|---|---|---|---|---|---|
| Q2 FY2027ended Dec 31, 2026 | Feb 9, 2027Expected | – | – | – | – |
| Q1 FY2027ended Sep 30, 2026 | Nov 10, 2026after the close | $1.10M | +1000.0% | – | Release |
| Q4 FY2026ended Jun 30, 2026 | Aug 28, 2026before the open | – | – | – | Release |
| Q3 FY2026ended Mar 31, 2026 | May 12, 2026after the close | – | – | – | Release |
| Q2 FY2026ended Dec 31, 2025 | Feb 10, 2026after the close | – | – | – | Release |
| Q1 FY2026ended Sep 30, 2025 | Nov 12, 2025after the close | $100.00K | – | – | Release |
| Q4 FY2025ended Jun 30, 2025 | Sep 5, 2025before the open | – | – | – | Release |
| Q3 FY2025ended Mar 31, 2025 | May 2, 2025before the open | – | – | -$0.49 | Release |
| Q2 FY2025ended Dec 31, 2024 | Feb 10, 2025after the close | $200.00K | – | $0.48 | Release |
| Q1 FY2025ended Sep 30, 2024 | Nov 12, 2024after the close | – | – | -$0.46 | Release |
| Q4 FY2024ended Jun 30, 2024 | Sep 20, 2024after the close | – | – | – | Release |
| Q3 FY2024ended Mar 31, 2024 | May 13, 2024after the close | – | – | -$0.71 | Release |
| Q4 FY2023ended Jun 30, 2023 | Sep 21, 2023before the open | – | – | – | Release |
| Q4 FY2022ended Jun 30, 2022 | Sep 27, 2022after the close | – | – | – | Release |
| Q3 FY2022ended Mar 31, 2022 | May 12, 2022after the close | $1.90M | – | -$0.06 | Release |
| Q2 FY2022ended Dec 31, 2021 | Feb 14, 2022after the close | $200.00K | – | -$0.05 | Release |
| Q1 FY2022ended Nov 1, 2021 | Nov 15, 2021after the close | $211.00K | – | -$0.04 | Release |
| Q4 FY2021ended Jun 30, 2021 | Sep 27, 2021before the open | – | – | – | Filing |
| Q3 FY2021ended Mar 31, 2021 | May 17, 2021before the open | – | – | – | Filing |
| Q2 FY2021ended Dec 31, 2020 | Feb 16, 2021after the close | – | – | – | Filing |
| Q1 FY2021ended Sep 30, 2020 | Oct 13, 2020after the close | – | – | – | Filing |
Figures as first announced; later restatements appear under Financials. Expected dates are estimated from the company's past reporting pattern.
Guidance
iBio has not given guidance in its releases
Many companies give their outlook only on the conference call or not at all. When iBio puts a forecast in an earnings release, it is listed here with the exact sentence.
Press releases
Releases iBio filed with the SEC as exhibits to Form 8-K or 6-K
- Update
- Results
- Update
- Update
- Results
- News
- Update
- Results
- Update
- Update
- Update
- Update
- Results
- Update
- Results
See a number that looks wrong?